Virta Health announced today that it now works with more than 20 national and regional health plans, marking triple-digit growth.
San Francisco-based Virta Health, which develops type 2 diabetes reversal technology, has now grown 133% year-over-year with large insurer customers that now offer its treatment to self-funded employer groups, including Humana and Providence Health Plan.
The company said in a news release that heightened demand for its diabetes reversal technology goes hand-in-hand with an industry-wide shift toward reversal as a method to treat diabetes. Virta said an analysis with methodology validated by the actuarial firm Milliman demonstrated payer savings of $425 per Virta patient per month, or $10,000 over the first two years.
Additionally, a consensus report from the American Diabetes Association, the Endocrine Society, the European Association for the Study of Diabetes, and Diabetes UK defined diabetes reversal for the first time while refining remission criteria, recognizing the apparent transition to diabetes reversal technology in the market.
“The tide is turning towards disease reversal as the primary goal for type 2 diabetes treatment,” Virta CEO & Co-Founder Sami Inkinen said in the release. “Our accelerating health plan growth affirms this shift, as payers race to cut costs while helping patients transform their health.”
